Lyon: Upped Pharmaron Beijing (03759) target price to HKD 28.8, maintaining "outperform" rating.
The bank believes that the raised guidance and increased accumulated orders of Conlong Chemicals towards the end of this year to next year are pleasing.
Lyon released a research report stating that Pharmaron Beijing (03759,300759.SZ) has raised its revenue growth guidance for 2025 from a year-on-year increase of 10% to 15%, to an increase of 12% to 16%, and expects adjusted net profit under non-international financial reporting standards to achieve double-digit growth. The bank believes that the upward revision of guidance and the increase in accumulated orders for Pharmaron Beijing for the end of this year to next year are commendable. Lyon has raised its revenue and net profit forecast for Pharmaron Beijing for the years 2025 to 2027, with a Hong Kong stock target price from 24.7 Hong Kong dollars to 28.8 Hong Kong dollars, and an A-share target price from 34.8 RMB to 40.6 RMB, maintaining an "outperform the market" rating.
Related Articles
Hymson Laser Technology Group (688559.SH) plans to launch a restricted stock incentive plan for 2,643,078 shares.
On October 31st, Taiwan (09890) invested 1.4775 million Hong Kong dollars to repurchase 100,000 shares.
MINIEYE (02431) signed a construction engineering construction contract with Henan Gejiu Construction.
Hymson Laser Technology Group (688559.SH) plans to launch a restricted stock incentive plan for 2,643,078 shares.
On October 31st, Taiwan (09890) invested 1.4775 million Hong Kong dollars to repurchase 100,000 shares.
MINIEYE (02431) signed a construction engineering construction contract with Henan Gejiu Construction.
RECOMMEND
First in History: NVIDIA’s Market Capitalization Tops $5 Trillion
30/10/2025
Congressional Budget Office Estimates Government Shutdown Has Cost the U.S. Economy $18 Billion
30/10/2025
Wall Street on China’s Internet Sector: Distinct Investment Opportunities in AI and Gaming; Caution on E‑commerce
30/10/2025
